AlzeCure Pharma AB (“AlzeCure” or “the Company”) announced on November 2, 2018 its intention to list the Company’s shares on Nasdaq First North Premier Growth Market in Stockholm and published. The Company has therefore published a prospectus that has been approved by and registered with Finansinspektionen, the Swedish Financial Supervisory Authority.

The Board believes that the time is right to broaden the Company’s shareholder base and apply for listing of the company’s shares on Nasdaq First North Premier Growth Market. The Board estimates that a listing would increase the possibilities of funding the company’s expansion, increase visibility and commercial capacity, and have a positive effect on the company’s relationships with partners and potential customers.

The Board of AlzeCure Pharma has applied for and obtained approval, on condition that the distribution requirement is met, regarding permission to trade the Company’s shares on Nasdaq First North Premier Growth Market. The estimated first day of trading in the shares on Nasdaq First North Premier Growth Market is 28 November 2018.

The ticker for the company’s shares on Nasdaq First North Premier Growth Market is ALZCUR.